TY -的T1 DaTscan发现轻度认知障碍患者,阿尔茨海默病和痴呆与路易小体(in3 - 1.008) JF -神经学乔-神经病学SP - in3 1.008 - 1.008 LP - in3六世- 80 - 7补充AU -布拉德利Boeve AU - Val劳盟Kejal Kan首页tarci AU -坦尼斯Ferman AU -迈克尔·西尔柏AU - Erik圣路易斯AU -格伦·史密斯AU -罗伯特Ivnik盟David Knopman AU -克利福德杰克盟罗纳德·彼得森Y1 - 2013/02/12 UR - //www.ez-admanager.com/content/80/7_Supplement/IN3-1.008.abstract N2 -目的:比较研究结果之间DaTscan轻度认知障碍(MCI)患者,阿尔茨海默病(AD)和路易体痴呆(下文)。背景:DaTscan反映了多巴胺缺乏striatonigral吸收减少,这一发现是典型的下文。人会预测MCI患者微不足道的帕金森症但有其他特性表明潜在的路易身体疾病(精神的小黑裙)病理(例如,REM睡眠行为障碍(RBD)和/或nonamnestic MCI (naMCI)]将会减少striatonigral吸收相比,那些广告或遗忘MCI (aMCI),但在广告和MCI将吸收大于在下文。设计/方法:DaTscan成像进行3 - 6小时后注射3 - 5 mCI的123我Ioflupane (DaTscan)。roi被放置在左、右每个主题的内果皮。相同的roi是放在同侧枕叶皮层组织。的左右壳枕比率(mPOR)吸收为每个病人进行了分析。结果:25个学科(平均年龄71岁,23岁男性)都经历了DaTscan。UPDRS分数高下文而MCI和广告。为每个综合症是MCI的mPOR±SD (n = 8): 2.00±0.53 (aMCI (n = 3): 2.33±0.24, naMCI (n = 5): 1.80±0.57),广告(n = 5): 2.59±0.57,和下文(n = 12): 1.27±0.27。所有naMCI和下文主题和1 aMCI RBD。使用mPOR 2.1,所有RBD病例,但1值& lt; 2.1。结论:预测,striatonigral吸收下文最低和最高的广告。 Uptake in those with naMCI and/or RBD is more similar to DLB while those with aMCI and/or absence of RBD is more similar to AD. Further work in much larger numbers of MCI subjects (with an adequate number of females) will determine the potential utility of DaTscan in differentiating underlying LBD from AD in those with MCI.Supported by: GE Healthcare, NIA grants P50 AG016574 and RO1 AG015866, the Mangurian Foundation, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation.Disclosure: Dr. Boeve has received research support from Cephalon, Inc.; Allon Therapeutics; and GE Healthcare. Dr. Lowe received personal compensation for consulting from Bayer Pharmaceuticals. Dr. Lowe received research grants from GE Health Care, Siemens Molecular Imaging, and AVID Radiopharmaceuticals, Inc. Dr. Kantarci has received compensation from Takeda Global Research & Development Center for serving as an advisory board member for research support. Dr. Ferman has nothing to disclose. Dr. Silber has nothing to disclose. Dr. St. Louis has receieved personal compensation for activities with Inspire, Inc. for serving as a member of Adverse Events Adjudication Committee. Dr. Smith has nothing to disclose. Dr. Ivnik has nothing to disclose. Dr. Knopman has received personal compensation for activities with Eli Lilly & Company. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from TauRx. Dr. Jack has received personal compensation for activities with Janssen, Eisai Inc., General Electric, Johnson & Johnson, and Eli Lilly & Company. Dr. Jack has received research support from Pfizer Inc, Allon, and Baxter. Dr. Jack has received research support from Allon and Baxter. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., Janssen Alzheimer's Immunotherapy, Elan Pharmaceuticals, GE Healthcare, and Novartis.Monday, March 18 2013, 8:00 am-12:00 pm ER -